TRANSGENE: €35.6 Million in Cash and Cash Equivalents as of March 31, 2018

information fournie par Boursorama •26/04/2018 à 17:45

€35.6 Million in Cash and Cash Equivalents as of March 31, 2018

- First patients treated in 2 clinical trials since the beginning of the year
- Clinical trials now on-going with 5 immuno-therapeutics
- Clinical readouts expected for each of our 5 products in 2018



Strasbourg, France, April 26, 2018, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies against cancers and infectious diseases, today announces its business update for the quarter ending March 31, 2018.

.../...


As of March 31, 2018, government financing for research expenditures mainly consisted of 25% of the research tax credit expected for 2018 (€1.6 million in the first quarter of 2018, comparable with the same period in 2017).